Literature DB >> 26165239

The use of plasmapheresis in a 4-year-old boy with toxic epidermal necrosis.

Joanna Hinc-Kasprzyk1, Agnieszka Polak-Krzemińska, Monika Głowacka, Irena Ożóg-Zabolska.   

Abstract

BACKGROUND: Toxic epidermal necrosis (TEN) is a severe and life-threatening syndrome manifesting as extensive necrosis of the epidermis and mucous membranes accompanied by systemic symptoms. The causative factor is exposure to drugs, such as sulphonamides, antiepileptic preparations, non-steroidal anti-inflammatory drugs and paracetamol. The mechanism leading to the development of lesions is unknown and there is no uniform strategy of management. CASE REPORT: A 4-year-old boy was admitted with late-stage TEN; he was additionally affected by partial atrophy of the corpus callosum, mental retardation and drug-resistant epilepsy. Three weeks before the first symptoms developed, antiepileptic treatment was widened with lamotrigine, which seems to be the causative factor of TEN. Since general and topical pharmacological therapy failed, plasmapheresis was applied and already after 2 cycles, the progression of lesions was inhibited and circulation was gradually stabilized.
CONCLUSIONS: The use of plasmapheresis in a child with TEN can result in substantial improvement of the general and local condition. The case presented clearly indicates that standards of management of children with suspected or developed TEN should be urgently instituted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165239     DOI: 10.5603/AIT.2015.0034

Source DB:  PubMed          Journal:  Anaesthesiol Intensive Ther        ISSN: 1642-5758


  2 in total

1.  Management of Toxic Epidermal Necrolysis with Plasmapheresis and Cyclosporine A: Our 10 Years' Experience.

Authors:  Giuseppe Giudice; Giulio Maggio; Loredana Bufano; Giuseppe Memeo; Michelangelo Vestita
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-02-22

2.  Toxic epidermal necrolysis in an 8-year-old girl successfully treated with cyclosporin A, intravenous immunoglobulin and plasma exchange.

Authors:  Marzena Zielińska; Łukasz Matusiak; Waldemar Gołębiowski; Katarzyna Swiątek; Iwona Chlebicka; Joanna Maj; Jacek Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.